<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04184089</url>
  </required_header>
  <id_info>
    <org_study_id>ANES.CE.01</org_study_id>
    <nct_id>NCT04184089</nct_id>
  </id_info>
  <brief_title>High Flow Nasal Cannula in Patients Undergoing Endoscopic Retrograde Cholangiopancreatography With Intravenous Sedation.</brief_title>
  <official_title>High Flow Nasal Cannula in Patients Undergoing Endoscopic Retrograde Cholangiopancreatography With Intravenous Sedation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>American University of Beirut Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>American University of Beirut Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      High flow nasal cannula provides adequate oxygenation in patients with compromised pulmonary&#xD;
      function. Very few studies in the literature addressed its use with IV sedation in the OR.&#xD;
      Successful application of High Flow nasal cannula in intravenous deep sedation cases in the&#xD;
      OR will benefit in the reduction of airway manipulation and side effects from general&#xD;
      anesthesia.&#xD;
&#xD;
      This study aims to find out the optimal nasal cannula flow rate for maintenance of safe IV&#xD;
      deep sedation in endoscopic retrograde cholangiopancreatography (ERCP) patients and to assess&#xD;
      gastroenterologist and patient satisfaction.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 25, 2020</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Optimal flow rate</measure>
    <time_frame>During the surgery</time_frame>
    <description>The optimal flow rate stabilized for the patient which is determined by the oxygen saturation (%)</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>High-flow Nasal Cannula</condition>
  <condition>Intravenous Sedation</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>High flow rate of 5 L/min and FiO2 of 40%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nasal cannula at flow rate of 15 L/min and FiO2 of 40%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nasal cannula at flow rate of 30 L/min and FiO2 of 40%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nasal cannula at flow rate of 60 L/min and FiO2 of 40%</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>High flow nasal cannula (15 L/m)</intervention_name>
    <description>nasal cannula at a flow rate of 15 l/min and FiO2 of 40%</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>High flow nasal cannula (30 L/m)</intervention_name>
    <description>nasal cannula at a flow rate of 30l/min and FiO2 of 40%</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>High flow nasal cannula (60 L/m)</intervention_name>
    <description>nasal cannula at flow rate of 60L/min. Oxygen supplementation will be at an FiO2 of 40%.</description>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient able to give consent.&#xD;
&#xD;
          2. Patient undergoing deep sedation.&#xD;
&#xD;
          3. Patient undergoing ERCP procedure with no restrictions on the duration of the&#xD;
             procedure.&#xD;
&#xD;
          4. Age &gt; 18 years&#xD;
&#xD;
          5. Patients with BMI &lt; 40 kg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient unable to give consent&#xD;
&#xD;
          2. Patient refusal to participate&#xD;
&#xD;
          3. Patients undergoing general anesthesia&#xD;
&#xD;
          4. age less than 18 years old&#xD;
&#xD;
          5. Patients with severe heart failure (EF&lt;30%)&#xD;
&#xD;
          6. Morbidly obese Patients with BMI &gt; 40 kg/m2&#xD;
&#xD;
          7. Patients with sleep apnea&#xD;
&#xD;
          8. Claustrophobia&#xD;
&#xD;
          9. Risk of aspiration due to severe reflux&#xD;
&#xD;
         10. Facial injury, facial malformation&#xD;
&#xD;
         11. Nasal defects/obstruction&#xD;
&#xD;
         12. ASA 4 patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Fadia Shebbo, MSc</last_name>
    <phone>+9611350000</phone>
    <phone_ext>5380</phone_ext>
    <email>fs97@aub.edu.lb</email>
  </overall_contact>
  <location>
    <facility>
      <name>Christine El-Yahchouchi</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine El-yahchouchi, M.D.</last_name>
      <phone>00-961-350-000</phone>
      <phone_ext>6380</phone_ext>
      <email>ce18@aub.edu.lb</email>
    </contact>
  </location>
  <location_countries>
    <country>Lebanon</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>October 11, 2019</study_first_submitted>
  <study_first_submitted_qc>December 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2019</study_first_posted>
  <last_update_submitted>March 29, 2021</last_update_submitted>
  <last_update_submitted_qc>March 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>American University of Beirut Medical Center</investigator_affiliation>
    <investigator_full_name>Christine El Yahchouchi</investigator_full_name>
    <investigator_title>Instructor of Clinical Specialty</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

